Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Julian Hardman

Diagnostic Radiology Las Vegas, NV Medical Doctor

NPI 1780908335 CMS profile 4219197

7130 Smoke Ranch Rd Ste 101, Las Vegas, NV 89128

Open in the dashboard

General payments

$23,891

261 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julian Hardman of Las Vegas, NV is reported in the CMS Open Payments database as having received $23,891 across 261 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,513 33
2024 General $3,459 38
2023 General $2,930 41
2022 General $3,413 46
2021 General $2,906 39
2020 General $2,622 30
2019 General $5,048 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julian Hardman
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Julian Hardman were reported at $3,513. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Julian Hardman Diagnostic Radiology median Middle half National median
2019 $5,048 $108 $29–$318 $163
2020 $2,622 $65 $21–$252 $114
2021 $2,906 $92 $24–$292 $132
2022 $3,413 $104 $29–$294 $149
2023 $2,930 $110 $29–$337 $160
2024 $3,459 $113 $30–$356 $164
2025 $3,513 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $15,948 132 payments
  2. Stryker Corporation $2,354 36 payments
  3. Medtronic, Inc. $1,867 30 payments
  4. MicroVention, Inc. $888 19 payments
  5. Viz.Ai, Inc. $532 2 payments
  6. Medtronic USA, Inc. $441 18 payments
  7. Sirtex Medical Inc $410 3 payments
  8. DePuy Synthes Sales Inc. $294 4 payments
  9. Inari Medical, Inc. $272 2 payments
  10. Shockwave Medical, Inc $195 1 payment
  11. Other $689 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,637 240 payments
  2. Travel and Lodging $6,254 21 payments
Products named General payments · program years 2019–2025
  1. Penumbra System Neurointervention $4,952 13 payments
  2. Penumbra System Neurointervention $2,394 21 payments
  3. Smart Coil $1,901 11 payments
  4. RED 72 $1,801 23 payments
  5. Smart $1,165 8 payments
  6. Penumbra Coil 400 $1,144 15 payments
  7. Penumbra SMART Coil $1,050 6 payments
  8. Penumbra Jet 7 $891 4 payments
  9. SURPASS EVOLVE $648 10 payments
  10. KYPHON EXPRESS II KYPHOPAK TRAY $633 12 payments
  11. Other $10,744 157 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

48

Median for Diagnostic Radiology: 24

Drug cost

$286

Median for Diagnostic Radiology: $190

Branded share of claims

100%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 48 $286

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 182 billing codes

Paid by Medicare

$204,950

Of which drugs: $405

Medicare patients

1,909

Average age 73

Services billed

4,454

1,041 women, 868 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 47%
Ischemic heart disease 45%
Chronic kidney disease 42%
Heart failure 38%
COPD 37%
Atrial fibrillation 34%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 14 1,400 $150

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record